SRR6013505
— · cohortA4
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA4
- subtype
- cohortA4
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.530
- E2F_TARGETS+0.490
- MYC_TARGETS_V1+0.390
- UNFOLDED_PROTEIN_RESPONSE+0.380
- G2M_CHECKPOINT+0.360
- OXIDATIVE_PHOSPHORYLATION+0.320
- DNA_REPAIR+0.270
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.250
- SPERMATOGENESIS+0.250
- MTORC1_SIGNALING+0.220
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.650
- INTERFERON_GAMMA_RESPONSE-0.570
- IL6_JAK_STAT3_SIGNALING-0.520
- HEDGEHOG_SIGNALING-0.460
- TNFA_SIGNALING_VIA_NFKB-0.450
- ALLOGRAFT_REJECTION-0.440
- INFLAMMATORY_RESPONSE-0.430
- KRAS_SIGNALING_UP-0.370
- IL2_STAT5_SIGNALING-0.360
- COMPLEMENT-0.340
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C3L-02649 | — | cohortMD1 | 0.890 |
| 2 | TCGA-55-7570-01A-11R-2039-07 | — | cohortA3 | 0.889 |
| 3 | ERR2208894 | — | — | 0.888 |
| 4 | TCGA-EW-A2FW-01A-11R-A17B-07 | — | B | 0.886 |
| 5 | BS_MV6ASWV9 | ATRT | — | 0.885 |
| 6 | SRR8518239 | — | E | 0.883 |
| 7 | C3N-03076 | — | cohortMD1 | 0.877 |
| 8 | TCGA-QK-A6VB-01A-12R-A34R-07 | — | — | 0.874 |
| 9 | 176e93be-1ae5-43f2-a0b5-17f31695e679 | — | — | 0.874 |
| 10 | BS_WVW3W6ZB | ATRT | — | 0.872 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.530 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.490 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.390 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.380 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.360 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.320 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.270 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.250 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.250 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.220 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.190 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.170 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.170 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.160 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.140 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.110 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.110 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.080 | Inavolisib | — uncovered |
| PEROXISOME | 0.030 | Idelalisib | — uncovered |